Immunotherapy in urothelial cancer: what
compounds?
1. Sunshine & Taube. Curr Opin Pharmacol 2015
PD-L1 inhibitors
PD-1 inhibitors
Atezolizumab
(engineered IgG1, no ADCC)
Durvalumab
(modified IgG1, no ADCC)
Avelumab
(modified IgG1, ADCC)
Nivolumab
(IgG4)
Pembrolizumab
(IgG4, humanised)
